Benny Chung-Ying ZEE (Hong Kong)

Prof. Benny Zee is Assistant Dean (Research) for the Faculty of Medicine and also Professor and Head of the Division of Biostatistics and Director of the Centre for Clinical Research and Biostatistics in the JC School of Public Health and Primary Care, Chinese University of Hong Kong (CUHK). He is Director of Clinical Trials and Biostatistics Lab in the CU Shenzhen Research Institute (SZRI) and serves as an Executive Committee member in the Centre for Entrepreneurship and holds honorary appointments in the Department of Clinical Oncology and the Department of Statistics of CUHK. He is also the Chairman of the Joint CUHK-NTEC Clinical Research Ethics Committee since 2006. Professor Zee obtained his Ph.D in Biostatistics from the University of Pittsburgh USA in 1987. He then joined the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) as Senior Biostatistician, and faculty member in the Department of Community Health and Epidemiology and the Department of Mathematics and Statistics of Queen’s University Canada from 1987-2001. He remains as Adjunct Professor with Queen’s University after he joined CUHK and is actively promoting international academic activities and collaborations.

Professor Zee has strong interest in various aspects of multi-centre clinical trials, including statistical methods, data management, drug and medical device development. He has experience in the development of efficient data management and “big data analytic” research using advanced computer technology, plus ample experience in working with industry to design and to carry out clinical trials that satisfy both academic interest and industry objectives. He has tremendous experience in the development of hospital infrastructure such as Ethics Committee, GCP Centre and Risk-based Quality Assurance team to carry out clinical research in hospitals that satisfies regulatory and international requirements. He is also active in medical devices development such as “automatic retinal imaging analysis (ARIA)” for the assessment of stroke risk and risk of dementia. The technology has obtained patents from USA, China and Taiwan, and is now being commercialized through Health View Bioanalytic Limited with support from the Technology Start-up Support Scheme for Universities (TSSSU) of the Innovation Technology Commission (ITC). He had published more than 217 international peer reviewed journal articles and serves in various committees including advisory committees for drug development and data & safety monitoring committees for international drug trials.